ATH

16.7%

0.7¢

ALTERITY THERAPEUTICS LIMITED

Market Cap $37.24M Add to my watchlist

Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Latest Threads

Tag

Subject

ATH Biotech

Stock price - ATH/ATHE

4 5 6

12:16

305

79K

12:16

Last post itsagas

305

79K

ATH

Frataxin works on oxidative damage on cell level

28/12/24

3.8K

28/12/24

Last post samfiodiving

3.8K

ATH

ATHE 3.18 in the end of trading

28/12/24

2.6K

28/12/24

Last post Scottsmyname

2.6K

ATH Biotech

Share cafe presentation - 13th Dec 2024

26/12/24

10K

26/12/24

Last post Scottsmyname

10K

ATH

Neurofilament light as prognostic marker in MSA

24/12/24

430

24/12/24

Last post Scottsmyname

430

ATH Biotech

Whats CXXT trade ?...manipulation ?

23/12/24

2.0K

23/12/24

Last post bj31

2.0K

ATH Biotech

All Alterity studies (PBT/ATH434) since 2019

21/12/24

1.8K

21/12/24

Last post Scottsmyname

1.8K

ATH

Why smoking decreases the risk of PD?

20/12/24

1.4K

20/12/24

Last post MrLearner

1.4K

See All Discussions

Timeline

Alterity Announces Completion of Phase 2 Clinical Trial
04 Dec 09:38	Share

Results of Meeting
22 Nov 11:33	Share

Presentation to Annual General Meeting
22 Nov 08:57	Share

Chairman's Address 2024 Annual General Meeting
22 Nov 08:51	Share

Change of Company Secretary
19 Nov 14:34	Share

ATH Presentation Tracking MSA Progression at Intl Symposium
12 Nov 10:10	Share

Alterity Announces Publication On ATH434 Mechanism of Action
06 Nov 09:17	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Oct 12:11	Share

Notice of Annual General Meeting
23 Oct 09:56	Share

ATH to Participate in 2024 Maxim Healthcare Virtual Summit
14 Oct 11:07	Share

Alterity Presents Data Describing Neuroprotection of ATH434
11 Oct 09:36	Share

Change of Share Registry
04 Oct 13:05	Share

Alterity Data Presentations at MDS Congress Raises Profile
02 Oct 11:43	Share

Alterity Therapeutics Filed Form 20-F and XBRL data with SEC
30 Sep 13:32	Share

ATH Appoints Abby Macnish Niven as Chief Financial Officer
30 Sep 09:00	Share

Appendix 4G
26 Sep 13:20	Share

Corporate Governance Statement
26 Sep 13:15	Share

Annual Report 2024
26 Sep 13:09	Share

Alterity to Deliver Multiple Presentations at MDS Congress
23 Sep 09:33	Share

Change of Director's Interest Notice - BM / PM
20 Sep 08:17	Share

Notification of cessation of securities - ATH
02 Sep 11:41	Share

Appendix 4E Preliminary Final Report
29 Aug 13:23	Share

Notification of cessation of securities - ATH
01 Aug 08:35	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Jul 08:12	Share

Alterity Therapeutics to Present at MST Financial Webinar
24 Jul 11:15	Share

Notice Under Section 708A
19 Jul 12:19	Share

Application for quotation of securities - ATH
19 Jul 12:17	Share

Proposed issue of securities - ATH
18 Jul 12:16	Share

Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
17 Jul 10:20	Share

Trading Halt
15 Jul 09:25	Share

View More

(20min delay)
Last 0.7¢		Change 0.001(16.7%)		Mkt cap ! $37.24M

Open	High	Low	Value	Volume
0.7¢	0.8¢	0.7¢	$604.0K	86.25M

Buyers (Bids)

No.	Vol.	Price($)
8	2199683	0.7¢

Sellers (Offers)

Price($)	Vol.	No.
0.8¢	42756643	43

View Market Depth

No.	Vol.	Price($)
8	2199683	0.007
25	35652994	0.006
49	39832655	0.005
45	33198935	0.004
61	94950559	0.003

Price($)	Vol.	No.
0.008	42756643	43
0.009	14120000	11
0.010	9600363	7
0.011	1810000	5
0.012	3948617	5

Last trade - 16.10pm 27/12/2024 (20 minute delay)

ATH (ASX) Chart

ALTERITY THERAPEUTICS LIMITED

Corporate Spotlight
Not Yet Available

Latest Threads

Timeline

Featured News

Latest Articles

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

An interim trial testing the effects of ATH434 on patients with MSA has yielded positive results for Alterity.

Alterity Therapeutics (ASX:ATH) doses first European patient in phase two MSA trial

Alterity Therapeutics (ASX:ATH) has dosed its first patient in Italy as part of its phase two clinical trial in multiple system atrophy (MSA).

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

ALTERITY THERAPEUTICS LIMITED

Corporate SpotlightNot Yet Available

Latest Threads

Timeline

Featured News

Latest Articles

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

An interim trial testing the effects of ATH434 on patients with MSA has yielded positive results for Alterity.

Alterity Therapeutics (ASX:ATH) doses first European patient in phase two MSA trial

Alterity Therapeutics (ASX:ATH) has dosed its first patient in Italy as part of its phase two clinical trial in multiple system atrophy (MSA).

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

Corporate Spotlight
Not Yet Available